RB1 and small cell lung carcinoma: Most of the discovered mutations observed in SCLC are passengers that do not essentially contribute to cancer cell growth, invasion or progression to metastatic lesions, and the most common mutations, that is, those in TP53 and RB1, are rarely targeted directly.